Alternative bimonthly cycles of doxorubicin, cyclophosphamide, and etoposide, cisplatin with hematopoietic growth factor support in patients with carcinoma of unknown primary site

被引:16
作者
Culine, S [1 ]
Fabbro, M [1 ]
Ychou, M [1 ]
Romieu, G [1 ]
Cupissol, D [1 ]
Pinguet, F [1 ]
机构
[1] Ctr Reg Lutte Contre Canc Val Daurelle, Dept Med Oncol, F-34298 Montpellier 5, France
关键词
chemotherapy; granulocyte-macrophage-colony stimulating factor; hematopoietic growth factor; unknown primary carcinoma;
D O I
10.1002/cncr.10264
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND. Because carcinomas of unknown primary origin are highly malignant tumors with a bad prognosis (median Survival, 6-12 months) and no current optimal therapy, the authors designed a prospective dose-dense chemotherapy regimen with the objective of improving the results observed in patients who receive conventional treatment. METHODS. Eighty-two patients received alternative bimonthly cycles of doxorubicin 50 mg/m(2) with cyclophosphamide 1000 mg/m(2) (AC) and etoposide 300 mg/m(2) with cisplatin 100 mg/m(2) (EP). Cycles were given at 2-week intervals with granulocyte-macrophage-stimulating factor support (5 mug/kg per day) from Day 4 to Day 10. Patients without measurable lesions were included, because the major end point was survival. RESULTS. The median number of alternative cycles of AC and EP was 4 cycles (range, 1-12 cycles). An objective response was observed in 24 of 62 patients (39%; 95% confidence interval, 30-48%) with measurable lesions, including 6 patients who achieved a complete response. Among 20 patients with nonmeasurable disease, 9 patients (45%) had no evidence of progressive disease at the end of chemotherapy. The overall median survival of 82 patients was 10 months, with 5 patients surviving clinically disease free at 17 months, 29 months, 45 months, 64 months, and 70 months after the end of treatment. Myelosuppression was the most common toxicity. Two toxic deaths occurred. CONCLUSIONS. Using these doses and schedules, a dose-dense chemotherapy regimen did not appear to improve the outcome of patients with carcinoma of unknown primary site. Alternative studies dealing with news drugs will be required. Cancer 2002;94:840-6. (C) 2002 American Cancer Society.
引用
收藏
页码:840 / 846
页数:7
相关论文
共 29 条
[1]   TREATMENT AND PROGNOSIS OF METASTATIC CARCINOMA OF UNKNOWN PRIMARY - ANALYSIS OF 100 PATIENTS [J].
ALBERTS, AS ;
FALKSON, G ;
FALKSON, HC ;
VANDERMERWE, MP .
MEDICAL AND PEDIATRIC ONCOLOGY, 1989, 17 (03) :188-192
[2]   FLUOROURACIL, DOXORUBICIN, CISPLATIN AND ALTRETAMINE IN THE TREATMENT OF METASTATIC CARCINOMA OF UNKNOWN PRIMARY [J].
BECOUARN, Y ;
BRUNET, R ;
BARBEGASTON, C .
EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1989, 25 (05) :861-865
[3]   Carboplatin plus paclitaxel in unknown primary carcinoma: A phase II Hellenic Cooperative Oncology Group study [J].
Briasoulis, E ;
Kalofonos, H ;
Bafaloukos, D ;
Samantas, E ;
Fountzilas, G ;
Xiros, N ;
Skarlos, D ;
Christodoulou, C ;
Kosmidis, F ;
Pavlidis, N .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (17) :3101-3107
[4]   Chemotherapy in carcinomas of unknown primary site: A high-dose intensity policy [J].
Culine, S ;
Fabbro, M ;
Ychou, M ;
Romieu, G ;
Cupissol, D ;
Pujol, H .
ANNALS OF ONCOLOGY, 1999, 10 (05) :569-575
[5]  
DECAMPOS ES, 1994, CANCER, V73, P470, DOI 10.1002/1097-0142(19940115)73:2<470::AID-CNCR2820730236>3.0.CO
[6]  
2-7
[7]   LACK OF VALUE FOR CISPLATIN ADDED TO MITOMYCIN-DOXORUBICIN COMBINATION CHEMOTHERAPY FOR CARCINOMA OF UNKNOWN PRIMARY SITE - A RANDOMIZED TRIAL [J].
EAGAN, RT ;
THERNEAU, TM ;
RUBIN, J ;
LONG, HJ ;
SCHUTT, AJ .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1987, 10 (01) :82-85
[8]   Mitomycin C, epirubicin and cisplatin versus mitomycin C alone as therapy for carcinoma of unknown primary origin [J].
Falkson, CI ;
Cohen, GL .
ONCOLOGY, 1998, 55 (02) :116-121
[9]  
GARROW GC, 1993, SEMIN ONCOL, V20, P287
[10]  
GILL I, 1991, ANTICANCER RES, V11, P1231